Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes

2 Feb 2007

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biosimilars and Bioanalytical Methods
Share to Monoclonal and Polyclonal Antibodies Research
Share to Protein purification and stability

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 17337334
DOI: 10.1016/j.biotechadv.2007.01.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changesPMID 17337334Read ↗

Development of therapeutic proteins: advances and challengesSemantic proximity Read ↗

Recent advances in (therapeutic protein) drug developmentSemantic proximity Read ↗

Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylationSemantic proximity Read ↗

Affordable mRNA Novel Proteins, Recombinant Protein Conversions and “Biosimilars”—Advice to Developers and Regulatory AgenciesSemantic proximity Read ↗

Molecular Engineering of Therapeutic CytokinesSemantic proximity Read ↗

Recombinant proteins for therapySemantic proximity Read ↗

Translational Proteomics for Transfusion Medicine: Resolution of the IVIG Proteomes of Different Geographically Sourced and Prepared IVIG ImmunotherapiesSemantic proximity Read ↗

Assessing the Manufacturability and Critical Quality Attribute Profiles of Anti-IL-8 Immunoglobulin G Mutant Variants.Semantic proximity Read ↗

Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies.Semantic proximity Read ↗

Impact of cell culture on recombinant monoclonal antibody product heterogeneitySemantic proximity Read ↗

Host cell proteins in biologics development: Identification, quantitation and risk assessmentSemantic proximity Read ↗

Transfusions of Blood Products Derived from Genetic Vaccine Recipients: Safety Concerns and Proposals for Specific MeasuresSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.